Literature DB >> 6571784

Do metastases arise from pre-existing subpopulations of cancer cells?

L Weiss, J C Holmes, P M Ward.   

Abstract

The hypothesis that metastases arise from pre-existing metastatic sub-populations of cancer cells with heritable metastasis-related characteristics, was tested by comparing the metastatic behaviour of cancer cells derived from pulmonary metastases with those from corresponding primary tumours, after implanting them subcutaneously in mice. In the case of KHT osteosarcomas and B16 melanomas, injected minces of metastases gave rise to more pulmonary metastases than cells derived from minces of the primary cancers generating them. However, in the case of 3LL and T241 cancers, the primary tumour minces gave rise to more pulmonary metastases than those derived from minced metastases. It is therefore concluded that the subpopulation hypothesis cannot be accepted as a general rule. When fragments of solid tumours were implanted into animals, no differences were detected between the metastatic behaviour of implants taken randomly from pulmonary metastases and the volume/age matched primary tumours generating them. These experiments thus provide no support for the hypothesis that metastases arise exclusively or predominantly from pre-existing metastatic subpopulations of cancer cells. Finally, implants of matched fragments from 3LL tumours of different volume and age, essentially produced no statistically significant differences in numbers of metastases. These observations do not therefore support the concept of a progressive evolution of subpopulations of cancer cells with heritable metastatic phenotypes during tumour growth.

Entities:  

Mesh:

Year:  1983        PMID: 6571784      PMCID: PMC2011239          DOI: 10.1038/bjc.1983.10

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  12 in total

1.  Metastasis results from preexisting variant cells within a malignant tumor.

Authors:  I J Fidler; M L Kripke
Journal:  Science       Date:  1977-08-26       Impact factor: 47.728

2.  Differences in the peripheries of Walker Cancer cells growing in different sites in the rat.

Authors:  L Weiss; J P Harlos
Journal:  Cancer Res       Date:  1979-07       Impact factor: 12.701

3.  Selection of successive tumour lines for metastasis.

Authors:  I J Fidler
Journal:  Nat New Biol       Date:  1973-04-04

4.  Do metastases metastasize?

Authors:  E V Sugarbaker; A M Cohen; A S Ketcham
Journal:  Ann Surg       Date:  1971-08       Impact factor: 12.969

5.  Immunologic studies of membrane mutants of a highly metastatic murine tumor.

Authors:  R S Kerbel
Journal:  Am J Pathol       Date:  1979-12       Impact factor: 4.307

6.  Factors influencing the quantitative estimation of the in vivo survival of cells from solid tumors.

Authors:  R F Kallman; G Silini; L M Van Putten
Journal:  J Natl Cancer Inst       Date:  1967-09       Impact factor: 13.506

7.  Metastasis: differences between cancer cells in primary and secondary tumors.

Authors:  L Weiss
Journal:  Pathobiol Annu       Date:  1980

8.  Metastasizing capacity of tumour cells from spontaneous metastases of transplanted murine tumours.

Authors:  R Giavazzi; G Alessandri; F Spreafico; S Garattini; A Mantovani
Journal:  Br J Cancer       Date:  1980-09       Impact factor: 7.640

9.  Metastatic inefficiency in mice bearing B16 melanomas.

Authors:  L Weiss; E Mayhew; D G Rapp; J C Holmes
Journal:  Br J Cancer       Date:  1982-01       Impact factor: 7.640

10.  Spontaneously metastasizing variants derived from MNU-induced rat mammary tumour.

Authors:  J C Williams; B A Gusterson; R C Coombes
Journal:  Br J Cancer       Date:  1982-04       Impact factor: 7.640

View more
  23 in total

1.  Spontaneous but not experimental metastatic activities differentiate primary tumor-derived vs metastasis-derived mouse prostate cancer cell lines.

Authors:  S J Hall; T C Thompson
Journal:  Clin Exp Metastasis       Date:  1997-11       Impact factor: 5.150

2.  Comments on 'In vivo selection of human renal carcinoma cells with high metastatic potenital in nude mice'.

Authors:  L Weiss
Journal:  Clin Exp Metastasis       Date:  1990 Jan-Feb       Impact factor: 5.150

3.  Caspase-3 expression in metastatic lymph nodes of esophageal squamous cell carcinoma is prognostic of survival.

Authors:  Xiu-Shen Wang; Kong-Jia Luo; Amos Ela Bella; Shan-Shan Bu; Jing Wen; Shui-Shen Zhang; Yi Hu
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

4.  The use of quantitative genetics for estimating the non-inherited and inherited contributions to metastasis formation.

Authors:  J P Volpe
Journal:  Clin Exp Metastasis       Date:  1992-05       Impact factor: 5.150

Review 5.  Role of the regional lymph node in cancer metastasis.

Authors:  T Tachibana; K Yoshida
Journal:  Cancer Metastasis Rev       Date:  1986       Impact factor: 9.264

Review 6.  Intratumoral heterogeneity: Clonal cooperation in epithelial-to-mesenchymal transition and metastasis.

Authors:  Deepika Neelakantan; David J Drasin; Heide L Ford
Journal:  Cell Adh Migr       Date:  2014-10-16       Impact factor: 3.405

7.  Influence of tumor transplantation methods on tumor growth rate and metastatic potential of solitary tumors derived from metastases.

Authors:  J P Volpe; L Milas
Journal:  Clin Exp Metastasis       Date:  1990 Jul-Aug       Impact factor: 5.150

8.  Different biological behavior of AKR lymphoma cells from primary and metastatic tumors.

Authors:  J Leibovici; Y Stark; S Kopel
Journal:  Experientia       Date:  1985-03-15

Review 9.  Clonal diversity in carcinomas: its implications for tumour progression and the contribution made to it by epithelial-mesenchymal transitions.

Authors:  J Guy Lyons; Erwin Lobo; Anna M Martorana; Mary R Myerscough
Journal:  Clin Exp Metastasis       Date:  2007-12-11       Impact factor: 5.150

10.  Metastasis and morphology of transplanted BR6 mouse mammary tumours.

Authors:  A E Lee; L S Pang; K Miller; L A Rogers
Journal:  Clin Exp Metastasis       Date:  1984 Jul-Sep       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.